Seizing Entrepreneurial Opportunities in Pudong: Embracing the Rise of Returnee Entrepreneurs
From November 9th to 11th, under the guidance of the United Front Work Department of the Shanghai Municipal Committee (Overseas Chinese Affairs Office of the Municipal Government), the “Overseas Chinese Innovation and Entrepreneurship Study Camp” (the 3rd Study Camp for Overseas Chinese Young Science and Technology Entrepreneurs and the 16th Study Camp for Overseas Chinese Returnees’ Entrepreneurship) was hosted by the United Front Work Department of the Pudong New Area Committee (Overseas Chinese Affairs Office of the District Government) and commenced in Zhangjiang. Focusing on the trend of overseas talent “returning” to China, the event aims to provide a platform for nurturing and fostering the innovation and entrepreneurship of young people in the overseas Chinese community who come to Shanghai, further strengthen exchanges with the new generation of overseas Chinese, and cultivate their patriotism and love for their hometown.
Meanwhile, Shanghai Television’s program “632 Observations” also conducted an interview with Kayla Yuan, a director at HB Ventures, to explore together the new opportunities being discovered by young overseas Chinese science and technology entrepreneurs.
Related Posts
NGS test completed in one day, lung and colon cancer test kits receive FDA approval
NGS (next generation sequencing technology), also known as high-throughput sequencing technology. It is commonly used for genetic disease screening, prenatal testing or diagnosis, oncology clinical diagnosis, pharmacogenomic testing, cancer chemotherapy and treatment, and single gene disease screening or diagnosis. It is capable of sequencing hundreds of thousa
Leto Laboratories Developing Semaglutide Biosimilar for Diabetes, Currently in Phase II Clinical Trial (2025)
Leto Laboratories is developing a Semaglutide biosimilar for diabetes and weight loss treatment, currently in Phase II clinical trials. The therapeutic candidate targets the GLP-1 receptor. According to GlobalData, Phase II diabetes drugs have a 38% success rate to advance to Phase III. Leto leverages its high-throughput screening and directional protein refold
Cancer Dx Firm Pillar Biosciences Gets $18M Investment From ORI Healthcare
NEW YORK (GenomeWeb) – Hong Kong-based venture capital group ORI Healthcare Fund announced today that it has made an $18 million investment in Boston-based cancer molecular diagnostics startup Pillar Biosciences. According to ORI, Pillar is advancing a patent-pending targeted sequencing technology platform and a proprietary data analysis toolkit, which offer
Next-Gen Automotive Semiconductors Critical for Level 5 Autonomous Vehicles (June 17, 2025)
Michigan engineers lead hardware innovations to enable AI chips required for full Level 5 autonomous driving. Achieving L5 autonomy demands faster, lower-power, and more durable semiconductors. E-Tronic, a leading Chinese automotive power semiconductor supplier, actively participates in next-gen automotive semiconductor development, supporting autonomous vehicl